The compound is a protein
inhibitor(抑制剂) which
binds9 to the enzyme (called
biotin生物素 protein ligase), stopping its action and interrupting the life cycle of the bacteria.
"Existing antibiotics target the bacterial cell
membranes10 but this potential new antibiotic operates in a completely different way," says Professor Andrew Abell, project leader and
Acting11 Head of the University's School of Chemistry and Physics.
Professor Abell says the compound, although at a very early stage of development -- it has not yet been tested on an animal model -- has the potential to become the first of a new class of antibiotics.
"Bacteria quickly build resistance against the known classes of antibiotics and this is causing a significant global health problem," he says. "Preliminary results show that this new class of compound may be effective against a wide range of bacterial diseases, including
tuberculosis12 which has developed a strain
resistant13 to all known antibiotics."
Developing the new protein inhibitor involved a novel approach called 'in situ click chemistry'. A selection of small
molecules14, or '
precursor15 fragments', are presented to the bacteria in a way so that the target protein enzyme itself builds the
inhibiting16 compound and also binds with it.
"In a sense the bacteria
unwittingly(不知不觉地) chooses a compound that will stop its growth and assembles it -- like building a weapon and using it against itself," says Professor Abell. "We've gone a step further to specifically engineer the enzyme so that it builds the best and most
potent1 weapon."
"Our results are
promising17. We've made the compounds; we know they
bind8 and
inhibit7 this enzyme and we've shown they stop the growth of a range of bacteria in the laboratory. The next critical step will be investigating their efficacy in an animal model."
"Thanks to this new approach what might have taken a year or more with a range of sequential experiments, we can now do in one single experiment," Professor Abell says.
The research has been published in the journal Chemical Science and is in
collaboration18 with researchers at Monash University and Adelaide's Women's and Children's Hospital.